

Synvista Therapeutics, Inc.  
Form 3  
August 20, 2007

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Atticus Capital LP

(Last) (First) (Middle)

152 W. 57TH STREET, 45TH  
FLOOR

(Street)

NEW YORK, NY 10019

(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

07/25/2007

3. Issuer Name **and** Ticker or Trading Symbol  
Synvista Therapeutics, Inc. [SYI]

4. Relationship of Reporting  
Person(s) to Issuer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_\_\_ Form filed by One Reporting  
Person  
\_X\_ Form filed by More than One  
Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

Date Expiration  
Exercisable Date

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title Amount or  
Number of  
Shares

4. Conversion  
or Exercise  
Price of  
Derivative  
Security

5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect  
(I)

6. Nature of Indirect  
Beneficial  
Ownership  
(Instr. 5)

(Instr. 5)

|                                                                     |       |            |                     |           |        |   |                  |
|---------------------------------------------------------------------|-------|------------|---------------------|-----------|--------|---|------------------|
| Series B Preferred Stock,<br>\$0.01 par value per share<br>(1)      | Â (2) | Â (3)      | Common<br>Stock     | 1,600,000 | \$ 2.5 | I | See Note (4) (5) |
| Series B Preferred Stock<br>Purchase Warrants (right<br>to buy) (1) | Â (2) | 07/25/2012 | Common<br>Stock (1) | 400,000   | \$ 2.5 | I | See Note (4) (5) |

## Reporting Owners

| Reporting Owner Name / Address                                                 | Relationships |           |         |       |
|--------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                | Director      | 10% Owner | Officer | Other |
| Atticus Capital LP<br>152 W. 57TH STREET, 45TH FLOOR<br>NEW YORK, NY 10019     | Â             | Â X       | Â       | Â     |
| ATTICUS MANAGEMENT LLC<br>152 W. 57TH STREET, 45TH FLOOR<br>NEW YORK, NY 10019 | Â             | Â X       | Â       | Â     |
| BARAKETT TIMOTHY R<br>152 W. 57TH STREET, 45TH FLOOR<br>NEW YORK, NY 10019     | Â             | Â X       | Â       | Â     |

## Signatures

/s/ Timothy R. Barakett, individually; as Managing Member of Atticus Management LLC; and on behalf of Atticus Capital LP, as Managing Member of Atticus Management LLC, its general partner, by Dennis Bertron, attorney-in-fact

08/20/2007

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Series B Preferred Stock Purchase Warrants represent the right to buy 400,000 shares of Series B Preferred Stock. Each share of Series B Preferred Stock is convertible into one share of Common Stock.

(2) Immediately

(3) None

Atticus Management LLC ("Atticus Management"), a Delaware limited liability company, and Timothy R. Barakett ("Mr. Barakett") are additional reporting persons. Mr. Barakett is the Chairman, Chief Executive Officer and Managing Member of Atticus Management.

(4) Atticus Management is the sole general partner of Atticus Capital LP, a Delaware limited partnership ("Atticus Capital"). Atticus Capital, together with certain of its affiliated entities (collectively, the "Atticus Entities"), acts as adviser for various investment funds (the "Funds") and managed accounts (the "Accounts").

(5) As a result, each of the reporting persons may be deemed to be a beneficial owner of the securities owned by the Funds and Accounts for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934. Mr. Barakett, Atticus Management and Atticus Capital disclaim beneficial ownership within the meaning of Rule 16a-1(a)(2) under the Securities Exchange Act of 1934 in the securities owned by the Funds and the Accounts except to the extent, if any, of their pecuniary interest therein.

Â

Remarks:

Edgar Filing: Synvista Therapeutics, Inc. - Form 3

Exhibit List: Exhibit 24 Power of Attorney, dated June 7, 2007

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.